With this, the original deal signed in December 2005 has been extended thrice and it now covers a range of drug discovery programs.
The programs use Argenta’s expertise in computer-aided drug design (CADD), medicinal chemistry, in-vitro biology and screening for discovering new chemical entities acting against undisclosed drug targets defined by Genentech.
The expanded agreement enables Genentech to continue placing projects directly to BioFocus, Galapagos’ other service division, which is responsible to offer Genentech with integrated medicinal chemistry, in-vitro biology and ADME services.
Galapagos SVP Services Chris Newton said the possibility for Genentech to continue placing projects directly with BioFocus also speaks to the complementary expertise and technological capabilities that Argenta and BioFocus possess.